Trodelvy

(sacituzumab govitecan) Gilead

Presentation:

Each vial contains 180 mg of Sacituzumab govitecan. Off-white to yellowish lyophilized powder in a single-dose vial.

Indications:

Trodelvy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.